Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Reslizumab (0.3 or 3.0 mg/kg) as Treatment for Patients (12-75 Years of Age) With Eosinophilic Asthma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating reslizumab at 0.3 or 3.0 mg/kg for eosinophilic asthma has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Asthma

Drugs mentioned

• reslizumab (reslizumab)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Eosinophilic Asthma | Phase 3 | Status: COMPLETED | Results posted: 2016-06-06